Solstice Oncology secures 225 million series A for immuno oncology therapy
Harbour BioMed partner Solstice Oncology secured 225 million in Series A financing to advance porustobart a novel neoadjuvant immuno oncology therapy targeting diverse cancer treatments
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.